A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to ...

Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts We initiated ...

The study of constructed αROR1‐CAR T cells showed an increase of PD-L1 expression when exposed to elevated pressure, driving resistance to CAR T cell-mediated cytotoxicity. However, the findings also ...

Dual PD-L1 and VEGF-A blockade with pumitamig plus chemotherapy yielded a 70% overall response rate and 100% disease control in evaluable first-line advanced NSCLC without actionable alterations.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

Adding Opdivo (nivolumab) and Yervoy (ipilimumab) to chemotherapy did not improve how long patients with HER2-negative ...

Selective removal of soluble tumor necrosis factor receptors by apheresis as a novel immunotherapy approach for triple-negative breast cancer. Outcomes with A+nP according to PD-L1 and aDDR status.

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, today announced the presentations of two studies in ...